1
|
Hu B, Gong Y, Wang Y, Xie J, Cheng J, Huang Q. Comprehensive Atlas of Circulating Rare Cells Detected by SE-iFISH and Image Scanning Platform in Patients With Various Diseases. Front Oncol 2022; 12:821454. [PMID: 35311070 PMCID: PMC8924462 DOI: 10.3389/fonc.2022.821454] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 02/07/2022] [Indexed: 12/23/2022] Open
Abstract
Objective Circulating rare cells (CRCs) are known as a crucial nucleated cellular response to pathological conditions, yet the landscape of cell types across a wide variety of diseases lacks comprehensive understanding. This study aimed at detecting and presenting a full spectrum of highly heterogeneous CRCs in clinical practice and further explored the characterization of CRC subtypes in distinct biomarker combinations and aneuploid chromosomes among various disease groups. Methods Peripheral blood was obtained from 2,360 patients with different cancers and non-neoplastic diseases. CRC capture and identification were accomplished using a novel platform integrating subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) strategy with a high-throughput automated image scanning system, on which hemocyte, tumor, epithelial, endothelial, mesenchymal, and stemness biomarkers were immunostained and displayed simultaneously. Double chromosome enumeration probe (CEP8 and CEP12) co-detection was performed on isolated CRCs from an extended trial for two chromosome ploidy patterns. Results A comprehensive atlas categorizing the diverse CRCs into 71 subtypes outlining was mapped out. The presence of epithelial-mesenchymal transition (EMT) or endothelial-mesenchymal transition (EndoMT), the cells with progenitor property, hematologic CRCs expressing multiple biomarkers, CRCs at "naked nuclei" status, and the rarely reported aneuploid mesenchymal epithelial-endothelial fusion cluster were described. Circulating tumor cells (CTCs) were detected in 2,157 (91.4%) patients; the total numbers of CTCs and circulating tumor-derived endothelial cells (CTECs) were relatively higher in several digestive system cancer types and non-neoplastic infectious diseases (p < 0.05). Co-detection combining CEP8 and CEP12 showed a higher diagnostic specificity on account of 57.27% false negativity of CRC detection through a single probe of CEP8. Conclusions The alternative biomarkers and chromosomes to be targeted by SE-iFISH and the image scanning platform, along with the comprehensive atlas, offer insight into the heterogeneity of CRCs and reveal potential contributions to specific disease diagnosis and therapeutic target cell discovery.
Collapse
Affiliation(s)
- Binjie Hu
- Molecular Diagnostics Laboratory of Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yanping Gong
- Molecular Diagnostics Laboratory of Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yulan Wang
- Molecular Diagnostics Laboratory of Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jianzhu Xie
- Molecular Diagnostics Laboratory of Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jin Cheng
- Molecular Diagnostics Laboratory of Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Qian Huang
- Molecular Diagnostics Laboratory of Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
2
|
Brunelli M, Nottegar A, Bogina G, Caliò A, Cima L, Eccher A, Vicentini C, Marcolini L, Scarpa A, Pedron S, Brunello E, Knuutila S, Sapino A, Marchiò C, Bria E, Molino A, Carbognin L, Tortora G, Jasani B, Miller K, Merdol I, Zanatta L, Laurino L, Wirtanen T, Zamboni G, Marconi M, Chilosi M, Manfrin E, Martignoni G, Bonetti F. Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. Am J Cancer Res 2015; 5:2212-2221. [PMID: 26328251 PMCID: PMC4548332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2015] [Accepted: 06/11/2015] [Indexed: 06/04/2023] Open
Abstract
Monosomy of chromosome 17 may affect the assessment of HER2 amplification. Notably, the prevalence ranges from 1% up to 49% due to lack of consensus in recognition. We sought to investigate the impact of monosomy of chromosome 17 to interpretation of HER2 gene status. 201 breast carcinoma were reviewed for HER2 gene amplification and chromosome 17 status. FISH analysis was performed by using double probes (LSI/CEP). Absolute gene copy number was also scored per each probe. HER2 FISH test was repeated on serial tissue sections, ranging in thickness from 3 to 20 µm. Ratio was scored and subsequently corrected by monosomy after gold control test using the aCGH method to overcome false interpretation due to artefactual nuclear truncation. HER2 immunotests was performed on all cases. 26/201 cases were amplified (13%). Single signals per CEP17 were revealed in 7/201 (3.5%) cases. Five out of 7 cases appeared monosomic with aCGH (overall, 5/201, 2.5%) and evidenced single signals in >60% of nuclei after second-look on FISH when matching both techniques. Among 5, one case showed amplification with a pattern 7/1 (HER2/CEP17>2) of copies (3+ at immunotest); three cases revealed single signals per both probes (LSI/CEP=1) and one case revealed a 3:1 ratio; all last 4 cases showed 0/1+ immunoscore. We concluded that: 1) monosomy of chromosome 17 may be observed in 2.5% of breast carcinoma; 2) monosomy of chromosome 17 due to biological reasons rather than nuclear truncation was observed when using the cut-off of 60% of nuclei harboring single signals; 3) the skewing of the ratio due to single centromeric 17 probe may lead to false positive evaluation; 4) breast carcinomas showing a 3:1 ratio (HER2/CEP17) usually show negative 0/1+ immunoscore and <6 gene copy number at FISH.
Collapse
Affiliation(s)
- Matteo Brunelli
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Alessia Nottegar
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Giuseppe Bogina
- Anatomic Pathology, Sacro Cuore Don Calabria HospitalNegrar, Italy
| | - Anna Caliò
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Luca Cima
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Albino Eccher
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | | | - Lisa Marcolini
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Aldo Scarpa
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
- ARC-NET Applied Research Centre, University of VeronaItaly
| | - Serena Pedron
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Eleonora Brunello
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Sakari Knuutila
- Department of Pathology, Laboratory of Molecular Cytogenetic, University of HelsinkiFinland
| | - Anna Sapino
- Department of Medical Sciences, Anatomic Pathology, University and Hospital TrustTurin, Italy
| | - Caterina Marchiò
- Department of Medical Sciences, Anatomic Pathology, University and Hospital TrustTurin, Italy
| | - Emilio Bria
- Medical Oncology, University and Hospital TrustVerona, Italy
| | | | - Luisa Carbognin
- Medical Oncology, University and Hospital TrustVerona, Italy
| | | | - Bharat Jasani
- Institute of Cancer & Genetics, Pathology, Cardiff UniversityUnited Kingdom
| | - Keith Miller
- UK NEQAS, University College of LondonUnited Kingdom
| | | | - Lucia Zanatta
- Anatomic Pathology, S. Maria di Ca’ Foncello HospitalTreviso, Italy
| | - Licia Laurino
- Anatomic Pathology, S. Maria di Ca’ Foncello HospitalTreviso, Italy
| | - Tiina Wirtanen
- Department of Pathology, Laboratory of Molecular Cytogenetic, University of HelsinkiFinland
- Department of Pathology, HUSLab, University Central HospitalHelsinki, Finland
| | - Giuseppe Zamboni
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
- Anatomic Pathology, Sacro Cuore Don Calabria HospitalNegrar, Italy
| | - Marcella Marconi
- Anatomic Pathology, Sacro Cuore Don Calabria HospitalNegrar, Italy
| | - Marco Chilosi
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Erminia Manfrin
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Guido Martignoni
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| | - Franco Bonetti
- Department of Pathology and Diagnostic, Anatomic Pathology, University and Hospital TrustVerona, Italy
| |
Collapse
|